<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927485</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol A2210108-UPR</org_study_id>
    <nct_id>NCT00927485</nct_id>
  </id_info>
  <brief_title>Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)</brief_title>
  <official_title>Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Puerto Rico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Puerto Rico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial Adenomatous Polyposis (FAP) is an autosomal dominant disorder characterized by the
      formation of multiple adenomatous colorectal polyps usually in the teenage years. Virtually,
      all patients with FAP will develop colorectal cancer on average by the 5th decade of life if
      prophylactic surgery is not performed. Besides, these individuals must have lifelong cancer
      surveillance of the remaining colorectum or ileum.

      Use of nonsteroidal anti-inflammatory drug (NSAID), such as sulindac, or celecoxib, which
      selectively inhibits prostaglandin synthesis primarily via the inhibition of cyclogenase-2
      (COX-2) have been shown to reduce the incidence and induce regression of adenomas in the
      rectum of patients with FAP. However, use of NSAIDs and COX-2 inhibitors is associated with
      significant comorbidity including renal and gastric toxicity and increased risk of vascular
      events. Therefore, identification of a chemopreventive agent that would have similar efficacy
      but less toxicity would enhance our ability to treat these patients. Therefore the following
      specific aim has been proposed:To determine in a randomized, double-blinded,
      placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal
      adenomas by measuring duodenal and colorectal/ileal polyp number, and polyp size in patients
      with FAP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to curcumin (2 curcumin pills twice a day for 12 months) or
      placebo (2 pills twice a day for 12 months). Besides, blood samples, risk factor
      questionnaire,and biopsies (upper endoscopy and sigmoidoscopy) will be obtained.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine in a randomized, double-blinded, placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp number, and polyp size in patients with FAP.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Familial Adenomatous Polyposis</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sugar pills)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcumin (Curcumin)</intervention_name>
    <description>Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Curcumin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Risk Factor Questionnaire</intervention_name>
    <description>Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Three tubes of blood at visits 0, 4 and 12 months.</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsies (Sigmoidoscopy)</intervention_name>
    <description>Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsies (Upper endoscopy)</intervention_name>
    <description>Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21-85 years with FAP (with an intact colon or who have had surgery)

        Exclusion Criteria:

          -  Mentally incompetent

          -  Female patients of childbearing age not on effective birth control

          -  Patients with WBC &lt; 3,500/ml, platelet count &lt; 100,000/ml, BUN &gt; 25mg%, creatinine &gt;
             1.5mg%

          -  Patients unable to stop NSAIDS or aspirin use for the duration of the study

          -  Malignancy other than nonmelanoma skin cancer

          -  Active bacterial infection

          -  Patients with GERD (Gastro esophageal reflux disease)

          -  Patients with a history of peptic (stomach or duodenal) ulcer disease

          -  Patients on Warfarin or anti-platelet drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcia R. Cruz-Correa, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Puerto Rico Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Puerto Rico Comprehensive Cancer Center</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Puerto Rico</investigator_affiliation>
    <investigator_full_name>Marcia R. Cruz-Correa, MD, PhD</investigator_full_name>
    <investigator_title>Director of Gastrointestinal Oncology</investigator_title>
  </responsible_party>
  <keyword>Familial Adenomatous Polyposis (FAP)</keyword>
  <keyword>Curcumin</keyword>
  <keyword>Colorectal polyps</keyword>
  <keyword>Duodenal polyps</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

